Details of the Drug Combinations

General Information of This Drug (ID: DM4ZBK6)

Drug Name
Fedratinib   DM4ZBK6
Synonyms TG101348
Indication
Disease Entry ICD 11 Status REF
Myelofibrosis 2A20.2 Approved [1]
Polycythemia vera 2A20.4 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Fedratinib + Panobinostat DC35123 Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
------------------------------------------------------------------------------------
4 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Fedratinib + Decitabine DC2MEJY Decitabine Myeloproliferative Neoplasm [5]
Fedratinib + Ivosidenib DC3LHZK Ivosidenib IDH Mutation [6]
Fedratinib + Enasidenib DCLPALM Enasidenib IDH Mutation [6]
Fedratinib + BMS-986158 DCYEMJG BMS-986158 Myelofibrosis [7]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 212327
3 TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT05524857) Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)
6 ClinicalTrials.gov (NCT04955938) A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
7 ClinicalTrials.gov (NCT04817007) A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)